Publicaciones en colaboración con investigadores/as de Instituto Valenciano de Oncologia (13)

2024

  1. Safety profile of trastuzumab deruxtecan in advanced breast cancer: Expert opinion on adverse event management

    Clinical and Translational Oncology

2023

  1. Neratinib + fulvestrant + trastuzumab for HR-positive, HER2-negative, HER2-mutant metastatic breast cancer: outcomes and biomarker analysis from the SUMMIT trial

    Annals of Oncology, Vol. 34, Núm. 10, pp. 885-898

  2. Triple-Negative PAM50 Non-Basal Breast Cancer Subtype Predicts Benefit from Extended Adjuvant Capecitabine

    Clinical cancer research : an official journal of the American Association for Cancer Research, Vol. 29, Núm. 2, pp. 389-400

2022

  1. Clinical and Sociodemographic Determinants of Adherence to World Cancer Research Fund/American Institute for Cancer Research (WCRF/AICR) Recommendations in Breast Cancer Survivors—Health-EpiGEICAM Study

    Cancers, Vol. 14, Núm. 19

  2. Type does matter. Use VIRGIN olive oil as your preferred fat to reduce your risk of breast cancer: case-control EpiGEICAM study

    European Journal of Clinical Nutrition, Vol. 76, Núm. 9, pp. 1343-1346

2021

  1. Palbociclib in combination with endocrine therapy versus capecitabine in hormonal receptor-positive, human epidermal growth factor 2-negative, aromatase inhibitor-resistant metastatic breast cancer: a phase III randomised controlled trial—PEARL

    Annals of Oncology, Vol. 32, Núm. 4, pp. 488-499

  2. Trajectories of alcohol consumption during life and the risk of developing breast cancer

    British Journal of Cancer, Vol. 125, Núm. 8, pp. 1168-1176

2020

  1. GEICAM Guidelines for the Management of Patients with Breast Cancer During the COVID-19 Pandemic in Spain

    Oncologist, Vol. 25, Núm. 9, pp. e1339-e1345

  2. Primary breast cancer and health related quality of life in Spanish women: The EpiGEICAM case-control study

    Scientific Reports, Vol. 10, Núm. 1

  3. Serum phospholipids fatty acids and breast cancer risk by pathological subtype

    Nutrients, Vol. 12, Núm. 10, pp. 1-18

2019

  1. Survival impact of primary tumor resection in de novo metastatic breast cancer patients (GEICAM/El Alamo Registry)

    Scientific Reports, Vol. 9, Núm. 1

2015

  1. Phase III trial evaluating the addition of bevacizumab to endocrine therapy as first-line treatment for advanced breast cancer:The Letrozole/Fulvestrant and Avastin (LEA) study

    Journal of Clinical Oncology

2010

  1. Maintenance treatment with Pegylated liposomal doxorubicin versus observation following induction chemotherapy for metastatic breast cancer: GEICAM 2001-01 study

    Breast Cancer Research and Treatment, Vol. 122, Núm. 1, pp. 169-176